211 related articles for article (PubMed ID: 34745960)
1. Identification of Gene-Set Signature in Early-Stage Hepatocellular Carcinoma and Relevant Immune Characteristics.
Zhao Q; Wongpoomchai R; Chariyakornkul A; Xiao Z; Pilapong C
Front Oncol; 2021; 11():740484. PubMed ID: 34745960
[TBL] [Abstract][Full Text] [Related]
2. Identification of Gene Signature as Diagnostic and Prognostic Blood Biomarker for Early Hepatocellular Carcinoma Using Integrated Cross-Species Transcriptomic and Network Analyses.
Al-Harazi O; Kaya IH; Al-Eid M; Alfantoukh L; Al Zahrani AS; Al Sebayel M; Kaya N; Colak D
Front Genet; 2021; 12():710049. PubMed ID: 34659334
[No Abstract] [Full Text] [Related]
3. Identification of the Tumor Immune Microenvironment and Therapeutic Biomarkers by a Novel Molecular Subtype Based on Aging-Related Genes in Hepatocellular Carcinoma.
Cai D; Zhao Z; Hu J; Dai X; Zhong G; Gong J; Qi F
Front Surg; 2022; 9():836080. PubMed ID: 35392063
[TBL] [Abstract][Full Text] [Related]
4. Identification and Validation of Ubiquitin-Specific Proteases as a Novel Prognostic Signature for Hepatocellular Carcinoma.
Ni W; Bian S; Zhu M; Song Q; Zhang J; Xiao M; Zheng W
Front Oncol; 2021; 11():629327. PubMed ID: 33718205
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Liver Progenitor Cell-Related Genes Signature Predicting Overall Survival for Hepatocellular Carcinoma.
Li X; Lin J; Pan Y; Cui P; Xia J
Technol Cancer Res Treat; 2021; 20():15330338211041425. PubMed ID: 34866477
[No Abstract] [Full Text] [Related]
6. Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.
Chen S; Zhao E
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101587. PubMed ID: 33662631
[TBL] [Abstract][Full Text] [Related]
7. Identification of Prognostic Glycolysis-Related lncRNA Signature in Tumor Immune Microenvironment of Hepatocellular Carcinoma.
Bai Y; Lin H; Chen J; Wu Y; Yu S
Front Mol Biosci; 2021; 8():645084. PubMed ID: 33968985
[No Abstract] [Full Text] [Related]
8. Significance of tumor-infiltrating immunocytes for predicting prognosis of hepatitis B virus-related hepatocellular carcinoma.
Chen QF; Li W; Wu PH; Shen LJ; Huang ZL
World J Gastroenterol; 2019 Sep; 25(35):5266-5282. PubMed ID: 31558872
[TBL] [Abstract][Full Text] [Related]
9. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
10. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
Mo Z; Liu D; Rong D; Zhang S
Front Immunol; 2021; 12():611058. PubMed ID: 33679749
[No Abstract] [Full Text] [Related]
11. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.
Peng Y; Liu C; Li M; Li W; Zhang M; Jiang X; Chang Y; Liu L; Wang F; Zhao Q
Cancer Cell Int; 2021 Feb; 21(1):98. PubMed ID: 33568167
[TBL] [Abstract][Full Text] [Related]
12. Identification and Validation of an Immune-Related eRNA Prognostic Signature for Hepatocellular Carcinoma.
Cai S; Hu X; Chen R; Zhang Y
Front Genet; 2021; 12():657051. PubMed ID: 34178028
[TBL] [Abstract][Full Text] [Related]
13. Identification of Gene Signatures for Diagnosis and Prognosis of Hepatocellular Carcinomas Patients at Early Stage.
Gan X; Luo Y; Dai G; Lin J; Liu X; Zhang X; Li A
Front Genet; 2020; 11():857. PubMed ID: 32849835
[TBL] [Abstract][Full Text] [Related]
14. An Inflammatory Response-Related Gene Signature Can Impact the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma.
Lin Z; Xu Q; Miao D; Yu F
Front Oncol; 2021; 11():644416. PubMed ID: 33828988
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis reveals a metabolic ten-gene signature in hepatocellular carcinoma.
Zhu Z; Li L; Xu J; Ye W; Chen B; Zeng J; Huang Z
PeerJ; 2020; 8():e9201. PubMed ID: 32518728
[TBL] [Abstract][Full Text] [Related]
17. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
Yan Z; He M; He L; Wei L; Zhang Y
Front Immunol; 2021; 12():723271. PubMed ID: 34925311
[TBL] [Abstract][Full Text] [Related]
18. Identification, Verification and Pathway Enrichment Analysis of Prognosis-Related Immune Genes in Patients With Hepatocellular Carcinoma.
Zhu Z; Song M; Li W; Li M; Chen S; Chen B
Front Oncol; 2021; 11():695001. PubMed ID: 34616672
[TBL] [Abstract][Full Text] [Related]
19. A novel 16-gene alternative mRNA splicing signature predicts tumor relapse and indicates immune activity in stage I-III hepatocellular carcinoma.
Chen XX; Zhang BH; Lu YC; Li ZQ; Chen CY; Yang YC; Chen YJ; Ma D
Front Pharmacol; 2022; 13():939912. PubMed ID: 36147313
[No Abstract] [Full Text] [Related]
20. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma.
Wang Z; Zhu J; Liu Y; Liu C; Wang W; Chen F; Ma L
J Transl Med; 2020 Feb; 18(1):67. PubMed ID: 32046766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
